Passing through the cycle of adversity and heading towards the second curve of the sea of stars of vaccine innovation###
There is no winter that will not pass. In life, there is always a part of the road to move forward with tears, which is the never-say-die strength in life.
In the long river of history, if there is a force that can travel through time and space and illuminate the world, it must be the power of innovation. Continuous innovation is the spark in the hands of Prometheus, innovators are fire thieves, and turning dreams into reality is a great force to adhere to long-termism.
In the course of many years of enterprise research, management guru Charles Handy found that the growth model of almost all enterprises follows an S-shaped curve, from beginning to end, it will go through the breaking point, the stall point and the limit point, from high growth to low growth, until the decline of the enterprise.
The launch of rockets requires more than one level of impetus, and the growth of enterprises also needs continuous iteration. The secret of trying to build an evergreen foundation and maintain the sustainable growth of the enterprise lies in the fact that before the first curve disappears, a new "S" curve has begun, and this new "S" curve is the second curve of the enterprise.
AIM has always been committed to "manufacturing conscientious vaccines and healthy people", and is the second largest vaccine group in China and the largest private vaccine group in the whole industry chain. It is the world's largest manufacturer of hepatitis B vaccine, the world's second largest manufacturer of rabies vaccine, and the only human vaccine company in China with strategic resources of P3 laboratory. AIM has 4 wholly-owned licensed vaccine manufacturers, 3 vaccine research institutes and 4 R&D centers.
AIM Vaccine has 8 commercialized vaccine products and 21 vaccine products under development, covering the world's top 10 vaccine varieties. The commercialized products have long occupied a leading position in the market, covering all 31 provinces, municipalities and autonomous regions in China, and reaching 2,000+ district and county centers for disease control and prevention.
AIM Vaccine Pipeline
Emmy realized early on that as a traditional vaccine company with the first curve, it would sooner or later reach the limit of its growth. Only by opening up the second curve, continuously increasing R&D investment, and laying out the iterative large-scale blockbuster vaccines that are urgently needed in the market, will we have a sustainable bright future.
Emmy attaches great importance to continuous R&D investment, and has been persevering for more than 10 years to be a change-maker in the industry. AIM Vaccine's R&D expenses in 2023 will exceed RMB 636 million, a year-on-year increase of 27.2%, and the proportion of R&D expenses to sales revenue will be 53.6%, far exceeding the industry average of similar vaccine companies.
We firmly believe that traditional products are "the leftover is king", and high-end large single products are "prosperous". The research and development of blockbuster vaccines is the real growth engine of AIM in the future. At present, AIM has 14 clinical approvals, 21 clinical trials, and 5 phase III clinical trials are in the final stage. Three iterative upgrade products, including 13-valent pneumococcal conjugate vaccine, serum-free iterative rabies vaccine, and 23-valent pneumococcal vaccine, were declared for marketing this year.
Today's Emmy, as if she is an "industrial innovation maniac", has created a scene that has never been seen before in the history of the industry. With great efforts, we have continued to develop 21 large-scale blockbuster vaccines, covering the world's top 10 blockbuster vaccines. While continuing the stock business of old products, it has firmly ignited the growth and development engine of the company's "second curve".
This is an unfinished voyage, from the blue wisps of the road to the sea of stars, from the traditional infectious vaccines to the blockbuster vaccines. Thousands of employees and hundreds of scientific research experts, with the heart of a child and the enthusiasm of pioneers, laid out 21 blockbuster vaccines for the future, and opened the journey of "poetry and wine, fighting the end of the world" for the declaration and listing of AIM blockbuster vaccines.
The iterative series of pneumonia conjugate vaccines represented by the 13-valent pneumococcal vaccine and the iterative series of rabies vaccines represented by the serum-free rabies vaccine will be declared for marketing this year, and the future of AIM vaccine will be better. It is believed that in the near future, the net profit brought by the launch of these two blockbuster vaccines is expected to catch up with the revenue of AIM Vaccine's existing vaccines.
Of course, among Emmy's blockbuster vaccine pipeline, there are also 20-valent pneumonia conjugate vaccine and 24-valent pneumonia conjugate vaccine with more cattle and greater market value. At the same time, it also lays out a human diploid rabies vaccine with better safety, as well as a safer and more effective mRNA rabies vaccine with fewer vaccinations.
On AIM & My's self-innovated mRNA technology platform, the mRNA respiratory syncytial virus vaccine (mRNA RSV vaccine) and mRNA herpes zoster vaccine that we are focusing on are the world's blockbuster single product vaccines, focusing on the unmet clinical needs in key disease areas, and further enhancing our innovation capabilities, core competitiveness and comprehensive strength.
In addition, AIM Vaccine has also made sufficient preparations for the internationalization of its products, and has considered the international layout in product development and production. According to the latest World Health Organization's 2024-2026 vaccine prequalification list, pneumonia conjugate vaccine and quadrivalent conjugate encephalitis vaccine are among the high-priority vaccine products, and the research and development of these two products is advancing rapidly. The hepatitis A vaccine, hepatitis B vaccine and rabies vaccine that have been marketed by the company are the products with priority certification, and these products have good market prospects in the world.
In 2023, AIM Vaccine has been favored by the capital market repeatedly. In March, it was included as a constituent stock of the Hang Seng Composite Index, in March it was included in Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, and in December it was included as a constituent stock of the MSCI Global Small Cap Index. At the same time, AIM Vaccine has decided to launch the A-share IPO plan, which is expected to further expand the company's popularity in the international capital market and introduce a more diversified investor group. The strategic goal of A+H's dual listing will provide a strong and inexhaustible impetus for the growth of Emmy's "second curve".
Those who lie for a long time will go far, those who lie for a long time will fly high, fish will ride by water, birds will ride by the wind, and people will ride by time. Follow the trend of the times, keep running, conquer the mountains with the original intention, and use the mission to level the ravines and dangerous shoals.
AIM Vaccine is entering the harvest period of flowering and fruiting, the coldest winter is about to pass, and the growth brought by the "second curve" is huge, which is a significant transformation and nirvana for AIM Vaccine. It will allow the AIM vaccine to have a longer and fresher flowering period.
In the near future, you will see Emmy's blockbuster vaccines coming like a sea of mountains, debuting in the market and taking root in the industry. AIM is expected to be the first to receive the admission tickets of world-class vaccine companies in China, and the AIM vaccine after Phoenix Nirvana will better demonstrate the bright future of China's vaccine industry, truly shoulder the mission of "leading industrial innovation with scientific and technological innovation", release new quality productivity, and ultimately bring higher and more lasting value returns to investors.
The year 2023 is extremely unusual, crossing the rapids and rapids of the economic downturn, passing through the turbulent waves of the capital market, and becoming more and more convinced that only days with wind and rain can carry the weight of life. Even if the current situation is difficult, the road ahead is still bright. Survive the winter of life, and when the spring is bright, the leaves will bloom, and the full branches will bear fruit.
Walking through the most thorny road, you will meet the light, survive the most biting winter, and usher in hope. There is no winter that will not pass, and there is no spring that will not come.
Founder, Chairman of the Board and CEO of AIM Vaccine
Extended
On the morning of April 15, 2024, it will be on the flight from Shenzhen to Hangzhou